Pacific Biosciences
PACB
107 hedge funds and large institutions have $281M invested in Pacific Biosciences in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 16 closing their positions.
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
1% more funds holding
Funds holding: 106 → 107 (+1)
0.05% more ownership
Funds ownership: 70.92% → 70.97% (+0.05%)
11% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 38
31% less capital invested
Capital invested by funds: $406M → $281M (-$125M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
99% less call options, than puts
Call options by funds: $5K | Put options by funds: $731K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$26.6M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$15.5M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$11.1M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
+$6.17M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$6.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Agricole
Montrouge Cedex,
France
|
-$77.8M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$10M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.61M |
| 4 |
Morgan Stanley
New York
|
-$2.71M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$2.05M |
PACB Hedge Fund Activity: Q2 2017 in Review
107 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2017, worth a combined $281M — down 31% from $406M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PACB positions and 16 closed out — a net gain of 1 holder — while 34 added to existing stakes and 38 trimmed.
The largest buyer was Capital World Investors, adding an estimated $26.6M. The largest seller was Credit Agricole, exiting entirely with an estimated $77.8M sold.
- 107 institutional investors held Pacific Biosciences (PACB) as of Q2 2017, up from 106 in Q1 2017.
- Funds reported $281M of Pacific Biosciences stock for Q2 2017, down 31% quarter-over-quarter.
- 17 funds opened new Pacific Biosciences positions in Q2 2017 and 16 closed out, a net change of +1 holder.
- The largest Pacific Biosciences buyer in Q2 2017 was Capital World Investors, an estimated $26.6M added.
- The largest Pacific Biosciences seller in Q2 2017 was Credit Agricole, an estimated $77.8M sold.
Based on aggregated 13F filings for Q2 2017.